Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients with Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-existing Liver and/or Renal Dysfunction

BACKGROUND: The safety and efficacy of frontline nilotinib and dasatinib in newly diagnosed chronic-phase chronic myelogenous leukemia (CML-CP) patients with pre-existing liver and/or renal dysfunction are unknown. PATIENTS AND METHODS: We analyzed adverse event rates, response rates, and survival r...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Clin Lymphoma Myeloma Leuk
Hoofdauteurs: Sasaki, Koji, Lahoti, Amit, Jabbour, Elias, Jain, Preetesh, Pierce, Sherry, Borthakur, Gautam, Daver, Naval, Kadia, Tapan, Pemmaraju, Naveen, Ferrajoli, Alessandra, O’Brien, Susan, Kantarjian, Hagop, Cortes, Jorge
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2015
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4769134/
https://ncbi.nlm.nih.gov/pubmed/26796981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2015.12.003
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items